secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001193125-24-151963
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Edward J. Dulac III resigns; CEO J. Scott Wolchko to assume CFO role effective June 14, 2024
--------------------------------------------------------------------------------

- Edward J. Dulac III resigned as CFO voluntarily, effective June 14, 2024; no disagreement with the company.
- CEO J. Scott Wolchko will succeed Dulac as CFO and principal financial/accounting officer immediately after resignation.
- Wolchko previously served as CFO from company inception until August 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/0001193125-24-151963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/d845254d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-151963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer